Who We Are

Tom Shea is the founding President of Xentria overseeing all aspects of business development, clinical, regulatory, and commercial operations. Tom is also the founding CEO of Meitheal Pharmaceutical, Inc., a generic pharmaceutical company focused on development, manufacture and supply of generic injectable products, which was established in January 2017.

Prior to joining Xentria and Meitheal, Tom was Vice President of Global Alliance Management for Sagent Pharmaceuticals and was responsible for global partnerships, supply chain and product development. Before his work at Sagent, Tom held various roles at APP, now Fresenius Kabi North America, in Commercial Operations and Business Development, focusing on Portfolio Management and National Accounts.

Tom started his pharmaceutical career as a Sales Rep at Fougera, now Sandoz. During his tenure at Fougera, he held positions of increasing responsibilities eventually attaining the position of National Sales Manager. Tom earned an M.B.A. from Notre Dame University and a B.A. in Philosophy from Marquette University.

Kirsten Anderson is Xentria’s Chief Operating Officer. Kirsten leads all strategic, operational, and clinical activities for Xentria. She is responsible for driving organizational vision, operational strategy, and translating strategy into actionable steps for growth. Kirsten is a clinical research leader specializing in growth strategy, with expertise in oncology drug development.  She has 30 years of experience in the biotech industry, most recently as Senior Vice President of Clinical Development at Presage Biosciences, responsible for strategic oversight of clinical research, including trial design, regulatory, operations, pharmacovigilance and biometrics. She has held leadership positions at OncoGenex, Sonus Pharmaceuticals, Xcyte Therapies, and Immunex. Kirsten earned a Master’s in Biotech Enterprise from Johns Hopkins University and has a bachelor’s degree in biology from the University of Vermont.

Kathleen leads the human resources function for the organization, overseeing employee relations, benefits, training, employee services, and developing company policies.

Tom has held various positions in clinical research in industry and academic settings. Prior joining Xentria, Tom served as a Senior Researcher at Olympus Corporation, focusing on interventional pulmonology solutions. His research career began at Northwestern University and Lurie Children’s Hospital of Chicago, primarily focused on asthma and cystic fibrosis therapeutics. Previous to this, Tom practiced as a Registered Respiratory Therapist in adult and pediatric critical care settings at various hospitals in Chicago and Indianapolis.

Tom holds a Bachelor of Science in Respiratory Care from Indiana University and a Master of Public Health, focused in Epidemiology and Healthcare Management, from Benedictine University. His research interests are centered in pulmonology, inflammatory disorders, critical care medicine, and rare diseases. His professional interests are centered in building and supporting efficient clinical development programs to fulfill unmet needs for suffering patients.

Noopur Singh is the Director of Medical Affairs overseeing Xentria’s advocacy efforts and fostering collaborative relationships with patient experts, key opinion leaders and clinical investigators. Motivated to eliminate challenges to drug access, Noopur is focused on strategic patient-centered drug development that bridges scientific gaps and cuts through the red tape across the drug supply chain.

Prior to Joining Xentria, Noopur was the Research Director at the Foundation for Sarcoidosis Research and played a key role in the development and execution of the organizations scientific research agenda. Before her time at FSR, Noopur was Clinical Site Manager Synexus Clinical Research in Chicago, responsible for the direction and execution of clinical trials. Prior to that, Noopur held various roles at Lurie Children’s Hospital of Chicago where she managed over 25 industry-sponsored trials and was an active participant in the Therapeutics Development Network with the Cystic Fibrosis Foundation. With over 10 years of both lab and clinical research experience in genetic and autoimmune-related rare diseases, her research interests focus on patient-centered outcomes and integrating the patient journey into drug development. Noopur earned a B.S. in Kinesiology from the University of Michigan.

Dionne Howe is the Associate Director of Clinical Operations and provides clinical operations leadership and oversight for all study activities, and determines operational processes, systems, and standards to support effective clinical program management and compliance across trials and locations.

Dionne earned an M.B.A. from Foster School of Business at the University of Washington Seattle and a B.A. in Chemistry from the University of North Carolina at Wilmington. She started her career working for a CRO as a bench scientist, then transitioned to Quality Assurance, R&D and Clinical Operations. Since 2003 Dionne has held positions in clinical research as a Clinical Research Coordinator, Clinical Research Associate, Clinical Study/Trial Manager and Clinical Project Manager. Prior to joining the Xentria Team in April 2022, Dionne was a Senior Clinical Project Manager at ICON – Biotech/Oncology.

Lidia is the organization’s senior financial executive, overseeing all aspects of finance, accounting, and strategic planning.